Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. - Santoni M; Myint ZW; Büttner T; Takeshita H; Okada Y; Lam ET; Gilbert D; Küronya Z; Tural D; Pichler R; Grande E; Crabb SJ; et al. (Cancer immunology, immunotherapy : CII, 2023)